JP6889171B2 - Ｔｌｒ７アゴニスト結晶形ａ、その調製方法及び使用 - Google Patents
Ｔｌｒ７アゴニスト結晶形ａ、その調製方法及び使用 Download PDFInfo
- Publication number
- JP6889171B2 JP6889171B2 JP2018540799A JP2018540799A JP6889171B2 JP 6889171 B2 JP6889171 B2 JP 6889171B2 JP 2018540799 A JP2018540799 A JP 2018540799A JP 2018540799 A JP2018540799 A JP 2018540799A JP 6889171 B2 JP6889171 B2 JP 6889171B2
- Authority
- JP
- Japan
- Prior art keywords
- crystal
- formula
- crystal form
- compound represented
- crystal composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *[n](ccc1nc(Cl)n2)c1c2Cl Chemical compound *[n](ccc1nc(Cl)n2)c1c2Cl 0.000 description 3
- OOPNBYLNZQFYEC-UHFFFAOYSA-N CCCCOc1nc(N)c2[nH]ccc2n1 Chemical compound CCCCOc1nc(N)c2[nH]ccc2n1 OOPNBYLNZQFYEC-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610082029.8A CN107043379A (zh) | 2016-02-05 | 2016-02-05 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| CN201610082029.8 | 2016-02-05 | ||
| PCT/CN2017/072891 WO2017133684A1 (zh) | 2016-02-05 | 2017-02-04 | 一种tlr7激动剂的晶型a、其制备方法和用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019505533A JP2019505533A (ja) | 2019-02-28 |
| JP2019505533A5 JP2019505533A5 (enExample) | 2020-02-27 |
| JP6889171B2 true JP6889171B2 (ja) | 2021-06-18 |
Family
ID=59499348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018540799A Active JP6889171B2 (ja) | 2016-02-05 | 2017-02-04 | Ｔｌｒ７アゴニスト結晶形ａ、その調製方法及び使用 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US10442811B2 (enExample) |
| EP (1) | EP3412672B1 (enExample) |
| JP (1) | JP6889171B2 (enExample) |
| KR (1) | KR102393280B1 (enExample) |
| CN (2) | CN107043379A (enExample) |
| AR (1) | AR107548A1 (enExample) |
| AU (1) | AU2017215801B2 (enExample) |
| CA (1) | CA3013518C (enExample) |
| CL (1) | CL2018002092A1 (enExample) |
| DK (1) | DK3412672T3 (enExample) |
| EA (1) | EA035951B1 (enExample) |
| ES (1) | ES2830443T3 (enExample) |
| HR (1) | HRP20201644T1 (enExample) |
| HU (1) | HUE051399T2 (enExample) |
| IL (1) | IL260968B (enExample) |
| LT (1) | LT3412672T (enExample) |
| MX (1) | MX374297B (enExample) |
| NZ (1) | NZ744884A (enExample) |
| PH (1) | PH12018501643A1 (enExample) |
| PL (1) | PL3412672T3 (enExample) |
| PT (1) | PT3412672T (enExample) |
| SG (1) | SG11201806683UA (enExample) |
| SI (1) | SI3412672T1 (enExample) |
| TW (1) | TWI754629B (enExample) |
| UA (1) | UA121161C2 (enExample) |
| WO (1) | WO2017133684A1 (enExample) |
| ZA (1) | ZA201805186B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| CN107043380A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| CN107043378A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
| CN107043379A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| US12128047B2 (en) | 2018-05-25 | 2024-10-29 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TLR7 agonist and pharmaceutical combination thereof for treating lung cancer |
| MX2021009496A (es) | 2019-02-08 | 2021-09-08 | Progeneer Inc | Complejo de colesterol-agonista del receptor 7 u 8 tipo larga distancia, y uso del mismo. |
| US12263172B2 (en) | 2019-03-15 | 2025-04-01 | Chia Tai Tianqing Pharmeceutical Group Co., Ltd. | Toll-like receptor agonists for use in the treatment of hepatitis b |
| EP3949967A4 (en) * | 2019-04-23 | 2023-01-18 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | SOLID PHARMACEUTICAL COMPOSITION WITH TLR7 AGONISTS |
| EP4115901A4 (en) | 2020-03-02 | 2024-04-10 | Progeneer Inc. | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
| WO2022031011A1 (ko) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | 동력학적으로 작용하는 아주번트 앙상블 |
| WO2022031021A1 (ko) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신 |
| US20230277525A1 (en) | 2020-08-04 | 2023-09-07 | Progeneer Inc | Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof |
| CN119431359A (zh) * | 2023-07-28 | 2025-02-14 | 苏州申拓医药科技有限公司 | 一种tlr7/8激动剂的可药用盐、晶型及其制备方法、药物组合物和用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3376479B2 (ja) * | 1991-08-12 | 2003-02-10 | 武田薬品工業株式会社 | 縮合ピリミジン誘導体、その製造法および用途 |
| EP1931352B1 (en) * | 2005-08-22 | 2016-04-13 | The Regents of The University of California | Tlr agonists |
| CA2745295C (en) | 2008-12-09 | 2017-01-10 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
| CA2826295C (en) * | 2011-02-04 | 2020-10-20 | Duquesne University Of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
| EP2800569B1 (en) | 2012-01-05 | 2018-07-25 | Northeastern University | Allosteric modulators of cb1 cannabinoid receptors |
| US9499549B2 (en) * | 2012-10-10 | 2016-11-22 | Janssen Sciences Ireland Uc | Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases |
| CN104780923B (zh) * | 2012-11-20 | 2017-03-15 | 葛兰素史克有限责任公司 | 干扰素诱导剂化合物 |
| RU2643371C2 (ru) * | 2012-11-20 | 2018-02-01 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Новые соединения |
| PE20151086A1 (es) * | 2012-11-20 | 2015-08-20 | Glaxosmithkline Llc | COMPUESTOS DERIVADOS DE 5H-PIRROLO-[3,2-d]PIRIMIDIN-4-AMINA 2,6,7 TRISUSTITUIDOS O 2,7 DISUSTITUIDOS COMO INDUCTORES DEL INTERFERON HUMANO |
| PL3137470T3 (pl) | 2014-05-01 | 2021-10-11 | Novartis Ag | Związki i kompozycje jako agonisty receptora toll-like 7 |
| CN105367576A (zh) | 2014-08-15 | 2016-03-02 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| AU2015303558B2 (en) | 2014-08-15 | 2018-07-12 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyrrolopyrimidine compounds used as TLR7 agonist |
| CN107043380A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| CN107043379A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
-
2016
- 2016-02-05 CN CN201610082029.8A patent/CN107043379A/zh active Pending
-
2017
- 2017-02-03 TW TW106103695A patent/TWI754629B/zh active
- 2017-02-04 EA EA201891768A patent/EA035951B1/ru not_active IP Right Cessation
- 2017-02-04 CA CA3013518A patent/CA3013518C/en active Active
- 2017-02-04 WO PCT/CN2017/072891 patent/WO2017133684A1/zh not_active Ceased
- 2017-02-04 ES ES17747004T patent/ES2830443T3/es active Active
- 2017-02-04 SG SG11201806683UA patent/SG11201806683UA/en unknown
- 2017-02-04 HU HUE17747004A patent/HUE051399T2/hu unknown
- 2017-02-04 MX MX2018009501A patent/MX374297B/es active IP Right Grant
- 2017-02-04 PL PL17747004T patent/PL3412672T3/pl unknown
- 2017-02-04 UA UAA201809129A patent/UA121161C2/uk unknown
- 2017-02-04 SI SI201730461T patent/SI3412672T1/sl unknown
- 2017-02-04 AU AU2017215801A patent/AU2017215801B2/en active Active
- 2017-02-04 PT PT177470044T patent/PT3412672T/pt unknown
- 2017-02-04 LT LTEP17747004.4T patent/LT3412672T/lt unknown
- 2017-02-04 JP JP2018540799A patent/JP6889171B2/ja active Active
- 2017-02-04 HR HRP20201644TT patent/HRP20201644T1/hr unknown
- 2017-02-04 DK DK17747004.4T patent/DK3412672T3/da active
- 2017-02-04 EP EP17747004.4A patent/EP3412672B1/en active Active
- 2017-02-04 CN CN201780009747.5A patent/CN108602831B9/zh active Active
- 2017-02-04 NZ NZ744884A patent/NZ744884A/en unknown
- 2017-02-04 KR KR1020187024627A patent/KR102393280B1/ko active Active
- 2017-02-04 US US16/075,297 patent/US10442811B2/en active Active
- 2017-02-06 AR ARP170100297A patent/AR107548A1/es not_active Application Discontinuation
-
2018
- 2018-08-01 ZA ZA2018/05186A patent/ZA201805186B/en unknown
- 2018-08-02 IL IL260968A patent/IL260968B/en unknown
- 2018-08-02 PH PH12018501643A patent/PH12018501643A1/en unknown
- 2018-08-03 CL CL2018002092A patent/CL2018002092A1/es unknown
-
2019
- 2019-09-25 US US16/582,575 patent/US10947245B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6889171B2 (ja) | Ｔｌｒ７アゴニスト結晶形ａ、その調製方法及び使用 | |
| JP6877450B2 (ja) | Ｔｌｒ７アゴニストのトリフルオロ酢酸塩及びその結晶形ｂ、調製方法、並びに使用 | |
| JP6898336B2 (ja) | Ｔｌｒ７アゴニストのマレイン酸塩、その結晶形ｃ、ｄ及びｅ、マレイン酸塩及び結晶形の調製方法及び使用 | |
| HK1259170B (zh) | 一种tlr7激动剂的晶型a、其制备方法和用途 | |
| HK1259175B (zh) | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e及其制备方法和用途 | |
| HK1259182B (zh) | 一种tlr7激动剂的三氟乙酸盐、晶型b、制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200120 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200120 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201126 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201201 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210226 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210427 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210520 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6889171 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |